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1. Introduction 
Prostate cancer is one of the most common malignancies in Western countries and the world 
(Baade et al., 2009). It is the third most common cause of death from cancer in men of all 
ages and the most common cause of death from cancer in men over age 75. The current 
standard therapies for prostate cancer include radiation, surgery, hormonal therapy and 
chemotherapy (Debruyne, 2002; Freytag et al., 2007; Nelius et al., 2009; Rozkova et al., 2009). 
Chemotherapy is almost always a salvage therapy for advanced prostate cancer, and 
chemoresistance is emerging problem in prostate cancer therapy. Strategies to overcome the 
chemoresistance of prostate cancer cells have not been developed partially because 
mechanisms of it are unknown and likely to be numerous. Chemoresistance has a tendency 
to occur both to clinically established therapeutic agents and novel targeted therapeutics 
implicating both intrinsic and acquired mechanisms of drug resistance (Djeu & Wei, 2009). 
Most likely, these are the mechanisms which are universal for cytoprotection from cell death 
induced by various factors. 
Cell death by apoptosis is one of the most universal mechanisms of cell response to injury. It 
plays the major role in carcinogenesis and prostate tumor progression. Suppression of 
apoptosis was proposed to cause inappropriate survival of genetically aberrant cells during 
carcinogenesis (Vineis, 2003). Cancer cells seem to be designed to propagate and survive in a 
new and hostile environment by suppressing their natural mechanisms of cell death. The 
neoplastic transformation of prostate epithelial cells is known to be associated with 
decreased apoptotic cell death (Inokuchi et al., 2009; Shilkaitis et al., 2000). The progression 
of prostate cancer, in particular, androgen-independent prostate cancer or prostate 
adenocarcinomas, was also shown to be associated with decreased apoptosis (Raffo et al., 
1995; Singh & Lokeshwar, 2009). The latter is the predominant form of tumor cell demise 
caused by chemotherapeutic agents and it plays an important role in cancer 
chemosensitivity and radiosensitivity (Arnold & Isaacs, 2002; Debes & Tindall, 2004). 
Targeting various mechanisms of apoptosis to cure prostate cancer has been suggested in 
many studies, naming potential molecular targets and key apoptotic regulators such as 
upstream and downstream caspases, p53, Phosphatase and tensin homolog (PTEN), prostate 
apoptosis response gene-4 (Par-4), Bcl-2 (B-cell lymphoma 2) protein, transcription factor 
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NF-kappa B, serine/threonine protein kinase and others (Uzzo et al., 2008; Wang et al., 
2004). Precisely, manipulating with sensitivity to cytotoxic agents to alter cancer progression 
has been suggested as a therapeutic approach for prostate cancer in some reports (McKenzie 
& Kyprianou, 2006; Watson & Fitzpatrick, 2005). However, for some reason, almost no 
attention was paid to apoptotic/cytotoxic endonucleases as potential targets. 
2. Cytotoxic endonucleases in normal prostate and prostate cancer cells 
Cytotoxic endonucleases, also called “apoptotic endonucleases,” are the initially recognized 
group of enzymes responsible for premortem and postmortem DNA fragmentation 
associated with cell death by apoptosis (Hengartner, 2001; Samejima & Earnshaw, 2005). 
Importantly, the same enzymes were later shown to provide DNA fragmentation that 
accompanies necrosis, autophagy, mitotic catastrophe and all other types of cell death. 
Therefore the term “apoptotic endonucleases” should be considered outdated. 
Major representatives of cytotoxic endonucleases include: deoxyribonuclease I (DNase I) 
(Polzar et al., 1993), deoxyribonuclease II (DNase II) (Krieser & Eastman, 1998), 
Endonuclease G (EndoG) (Li et al., 2001), caspase-activated DNase (CAD) (Enari et al., 1998), 
and DNase gamma (Shiokawa et al., 1997). Some of these enzymes, for example DNases I 
and II had been known before 1960s. However the actual role of the cytotoxic endonucleases 
was clarified much later. Cytotoxic endonucleases were found in all studied cells and 
tissues, including the prostate (Koizumi, 1995; Napirei et al., 2004). The enzymes belong to 
the family of hydrolyses that cleave phosphodiether bonds in DNA. They differ in certain 
catalytic characteristics and DNA sequence specificity, and yet produce very similar type of 
DNA damage consisting of single-stranded or double-strand DNA breaks. Most harmful 
and hard to repair DNA breaks and double-stranded. They can be produced by so called 
“single hit” or “double hit” mechanism. In a “single hit” mode, both DNA strands are cut 
simultaneously at the same site. This mechanism is mainly characteristic of DNase II. The 
much more common mechanism is “double hit,” in which strands are cleaved 
independently to result in a double-strand DNA break if the single-stranded breaks coincide 
with a 2-base or less shift between them. This mechanism is characteristic of DNase I and all 
other endonucleases, except DNase II.  
Independently from the mechanism, endonuclease-generated breaks have been shown to 
strongly interfere with DNA synthesis in both normal and cancer cells (Nagata, 2000). 
That is why, while sometimes considered downstream effectors of apoptotic cascades, the 
endonucleases can cause DNA fragmentation and imminent and irreversible cell death 
when acting alone after overexpression or introduction into the cell (Enari et al., 1998; 
Krieser & Eastman, 1998; Polzar et al., 1993). The endonucleases are commonly found 
active during cell death; however, the overall link between these enzymes and apoptosis 
is weak. Some of the endonucleases seem to be dispensable in normal apoptosis 
(Davidson & Harper, 2005; Irvine et al., 2005; Napirei et al., 2000). On the other hand, their 
participation in cell death in general after tissue injury seems crucial and evidence of this 
is overwhelming. Recent studies demonstrated that inactivation of the endonucleases 
causes protection of normal and cancer cells against a variety of injuries in vitro and in 
vivo (Basnakian et al., 2006; Basnakian et al., 2005; Napirei et al., 2006; Yin et al., 2007), 
suggesting that the endonucleases are essential for and mechanistically linked to injury-
related cell death. In addition to causing cell death itself, the endonuclease are certainly 
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essential for clean up after cell death, removal of DNA from blood plasma, and destroying 
“foreign” DNA from bacteria and viruses consumed by cells (Buzder et al., 2009). These 
roles of cytotoxic endonucleases are less relevant to prostate cancer and thus will not be 
considered in this review. 
Although all cells and tissues seem to express all endonucleases, the spectrum of them 
differs between the tissues. The reason for such redundancy of the cytotoxic endonucleases 
is not known, which allows speculation about the importance of DNA destruction from 
immediately prior to long after cell death. 
The most expressed and active endonuclease in normal prostate is DNase I, previously also 
known as Ca/Mg-dependent endonuclease (Kyprianou et al., 1988; Kyprianou & Isaacs, 
1988). Ca/Mg-dependent endonuclease-mediated DNA fragmentation is used as a marker 
of apoptosis in prostate cancer. The degradation of genomic DNA into nucleosome-sized 
fragments is an early event in castration-induced androgen withdrawal that involves death 
of the androgen-dependent epithelial cells following an increase of endonuclease activity 
(Banerjee et al., 2000; Brandstrom et al., 1994; Kyprianou et al., 1988). 
DNase I is found in all studied species and tissues (Lacks, 1981). It is expressed mainly in 
tissues of the digestive system, though the specific activity of the enzyme varies between the 
organs (Gonzalez et al., 2001; Jacob et al., 2002; Lacks, 1981). In digestive tissues (intestine, 
pancreas, salivary glands), it is a secreted enzyme intended to hydrolyze DNA in the 
alimentary tract. In non-digestive tissues (including prostate), the role of DNase I is not 
known. Bovine or mouse DNase I bind specifically to G-actin and blocks its 
polymerization (Lacks, 1981). The enzyme from all sources endonucleolytically cleaves 
double- or single-stranded DNA to 3'OH/5'P-end oligonucleotides, requires divalent 
cations, particularly Ca2+ and Mg2+, is inhibited by Zn2+, and has a neutral pH optimum. 
Inside the cell, the enzyme is located in the cytoplasm (Peitsch et al., 1993). It has also 
been shown inside nuclei, but the mechanism of its introduction into nuclei has not been 
studied. Inhibition of DNase I by internalized nuclear anti-DNA antibodies was shown to 
provide protection of cells against apoptotic stimuli (Madaio et al., 1996). No known 
nuclear localization signal was identified in DNase I, and “leakage” through nuclear pores 
was suggested (Polzar et al., 1993). Among various organs and tissues, prostate, pancreas, 
salivatory glands and kidney tubular epithelium have the highest levels of DNase I 
activity (Lacks, 1981; Polzar et al., 1993). Little is known about DNase I regulation in vivo. 
An alternative pre-mRNA splicing both in 5’UTR and in coding region was shown to be a 
mechanism of DNase I regulation (Basnakian et al., 1998; Basnakian et al., 2002). It is 
known that some DNase I isoforms can be generated by post-translational modification, 
namely mannose-type glycosylation of the protein (Lacks, 1981). 
Studies of endonucleases associated with prostate cancer are very limited. Usually 
neoplastic transformation is associated with the decrease of endonuclease expression and 
activity in various cancers, thus making them “immortal” (Banfalvi et al., 2007; Basnakian et 
al., 2006; Basnakian et al., 1991; Wang et al., 2008). The most profound decrease of 
endonuclease activity was observed in malignant invasive prostate and breast cancer cells 
(Basnakian et al., 2006; Wang et al., 2008). The decrease of endonuclease activity had been 
also observed in other cancers and models of carcinogenesis (Basnak'ian et al., 1989; 
Basnakian et al., 1991). Immortalization of rat fibroblasts with the S1A segment of SA7 
adenovirus also led to a significant decrease of endonuclease activity (Basnak'ian et al., 
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1989). Another report indicated that an endonuclease activity is decreased in 
diethylnitrosamine (DEN)-induced hepatomas in rats compared to normal liver tissue 
(Basnakian et al., 1991). The decrease was proportional to the degree of dedifferentiation 
and the activity was the lowest in poorly differentiated tumors. 
With the decrease of main prostate endonuclease, DNase I, the endonuclease activity in 
human prostate cancer cells is provided by EndoG. This endonuclease has a unique site-
selectivity, initially attacking poly(dG).poly(dC) sequences in double-stranded DNA, as 
denoted by this enzyme’s name. The enzyme also has RNase activity. EndoG 
predominantly resides in the intermembrane space of mitochondrion (Ohsato et al., 2002). 
Mammalian EndoG is synthesized as a 32 kDa propeptide in the cytoplasm and imported 
into mitochondria through a process mediated by its amino-terminal mitochondrion-
targeting sequence (Cote & Ruiz-Carrillo, 1993; Ruiz-Carrillo & Renaud, 1987). The EndoG 
protein precursor is inactive (Ikeda & Kawasaki, 2001). The signal peptide is cleaved off 
after entering the mitochondria and the mature active 27 kDa EndoG is released from 
mitochondria during apoptosis, moves to the nuclei and cleaves nuclear DNA without 
sequence specificity (Li et al., 2001). EndoG expression varies in different tissues and in 
embryonic tissues the expression of EndoG is very low (Apostolov et al., 2007b). As 
opposed to DNase I, the enzyme has a greater activity on single-stranded nucleic acid 
substrates, single-stranded DNA and RNA. It preferentially cleaves non-canonical 
structures of DNA, damaged DNA, triplex DNA, and R-loops that appear non-specifically 
during transcription (Masse & Drolet, 1999). Cisplatin-treated DNA was shown to be 
preferentially cleaved by EndoG (Ikeda & Ozaki, 1997). EndoG requires either Mn2+ or 
Mg2+ ions, and is inhibited 15-fold at physiological ionic strengths (Widlak et al., 2001). 
Fe2+ and Zn2+ inhibit the enzyme activity. The EndoG gene in mice is a single copy gene, 
which consists of 3 exons (Prats et al., 1997). The loss of EndoG activity in C.elegans 
resulted in increased cell survival (Hengartner, 2001). However, EndoG knockout mouse 
is viable (Irvine et al., 2005). Reduction of EndoG in C.elegans using siRNA or genetic 
mutation affected normal DNA degradation, as revealed by staining with TUNEL assay, 
and resulted in the delayed appearance of cell corpses during development in C.elegans 
(Parrish et al., 2001). Thus in comparison to other endonucleases, EndoG is uniquely 
compartmentalized in mitochondria and it does not have known intracellular inhibitors 
(like DNase I or CAD). The EndoG location site may indicate that this enzyme is not an 
instrument of immediate response to cell injury. 
EndoG seems to be particularly important in cancer cells because it regulates their 
sensitivity to chemotherapeutic agents (Basnakian et al., 2006). This report suggests the 
presence of EndoG in non-invasive breast cancer cells determines their sensitivity to 
apoptosis, which may be taken into consideration for developing the chemotherapeutic 
strategy for cancer treatment. In other cells, EndoG has been recognized as a key 
endonuclease in the caspase-independent apoptosis (Abbott et al., 2001; Bahi et al., 2006), 
mitotic catastrophe (Diener et al., ; Wang et al., 2008), and necrosis (Apostolov et al., 2007a; 
Jiang et al., 2006).  
Because anticancer drugs induce apoptosis in cancer cells through endonuclease-mediated 
DNA fragmentation (Ploski & Aplan, 2001; Shrivastava et al., 2000), and the inhibition of 
endonucleases has a protective effect (Shrivastava et al., 2000), endonuclease should be 
considered as important mediators of cancer cell death and potential therapeutic targets for 
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the anticancer therapy. However, delivery of endonucleases or modulation of endonuclease 
activity are not currently used for cancer therapy, in particular, for prostate cancer therapy.  
3. Modulation of EndoG by DNA methylation and histone deacetylation 
Epigenetic changes are believed to be the most common alteration at the DNA level in 
prostate cancer (Schulz & Hatina, 2006; Walton et al., 2008). Two types of DNA epigenetic 
changes that are known to occur in prostate cancer include regional DNA 
hypermethylation and regional/global DNA hypomethylation. Hypermethylation of the 
promoter region that contains CpG island occurs in a large number of genes and is 
usually associated with gene silencing in the vast majority of prostate cancer cases (Li et 
al., 2005; Perry et al., 2006; Rennie & Nelson, 1998). Studies have shown that 
hypermethylation of this region may be eventually used as a tumor biomarker for early 
diagnosis and risk assessment of prostate cancer. Furthermore, the prevalence of 
epigenetic changes in prostate cancer and the potential reversibility of DNA methylation 
alterations by DNA methylation inhibitors suggest that these changes are a viable target 
for cancer chemotherapy and chemoprevention strategies (Egger et al., 2004; Kopelovich 
et al., 2003; Yoo & Jones, 2006). 
Mammalian genome contains patterns of methylated cytosines for normal function, but 
until recently the structural organization of the methylation landscape of the human 
genome was unclear (Rollins et al., 2006). It has been reported that the human genome 
consists of short (<4 kb) unmethylated domains enriched in promoters, CpG islands, and 
first exons, embedded in a matrix of long methylated domains (Rollins et al., 2006). Analysis 
of promoter sequences of all known human cytotoxic endonucleases – described below - 
showed that EndoG is the only cytotoxic endonuclease that contains a CpG island, a 
segment of DNA with high G+C content and a site for methylation, in the promoter region 
(Wang et al., 2008). 
A large number of studies have shown that methylation of promoter CpG islands plays an 
important role in gene silencing (Ruchusatsawat et al., 2006; Taghavi & van Lohuizen, 
2006). The broadly accepted definition of a CpG island as a 200-bp fragment of DNA with 
G + C content greater than 50% and observed CpG/expected CpG ratio higher than 0.6 
failed to exclude many sequences (such as Alu repeats and unknown sequences) that are 
not associated with regulatory regions of genes (Takai & Jones, 2002). Recent studies 
indicate that the usage of a modified algorithm to search for CpG islands using a more 
stringent definition (G + C content higher than 55% and a length greater than 500 bp with 
observed CpG/expected CpG ratio 0.65) resulted in the exclusion of the majority of Alu 
repetitive and unknown sequences associated with the 5’ region of genes (Takai & Jones, 
2002). In view of these considerations, we applied this algorithm to the analysis of 
endonuclease genes, which could be regulated by DNA methylation. All known human 
cell death endonucleases and their sequence variants were analyzed using the CpG Island 
Searcher program (available at http://www.cpgislands.com (Takai & Jones, 2003)): 
DNase 1, DNase 1L1 variants 1, 2, 3 and 4; DNase 1L2, DNase 1L3 (DNase gamma), 
DNase 2ǂ, DNase 2ǃ variants 1 and 2, L-DNase II (LEI), CAD and EndoG. Surprisingly, 
this analysis showed that EndoG is the only gene that satisfied the criteria of containing a 
long CpG island in the promoter and exon 1 of the gene. 
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The methylation status of the EndoG promoter/exon 1 in prostate cancer cells was then 
determined by using the methylation-sensitive McrBC-PCR method. McrBC is a bacterial 
endonuclease, that does not act on unmethylated DNA, but cleaves DNA containing 5-
methylcytosine in one or both strands and thus nullifies PCR amplification (Nakayama et 
al., 2004). This experiment showed that in three studied prostate cancer cell lines, LNCaP, 
22Rv1 and PC3, EndoG promoter methylation was the lowest in 22Rv1 cells and highest in 
PC3 cells. Further comparison of the three prostate cancer cell lines showed that EndoG is 
highly expressed in 22Rv1 and LNCaP cells. In PC3 cells, EndoG was not expressed and the 
EndoG gene CpG island was hypermethylated (Wang et al., 2008). 
The expression of EndoG correlated positively with sensitivity to docetaxel, cisplatin and 
etoposide, and the silencing of EndoG by siRNA decreased the sensitivity of the cells to 
the chemotherapeutic agents in the two EndoG-expressing cell lines. To determine 
whether the level of EndoG expression affects the sensitivity of prostate cancer cells to 
chemotherapeutic drugs, we exposed the three cell lines to two anticancer agents, 
cisplatin (0-100 µM) and etoposide (0-300 µM), which are known to induce cell death in 
vitro (Fang et al., 2004; Lee et al., 2006). As expected, the two cell lines that expressed 
EndoG, 22Rv1 and LNCaP, were highly sensitive to both chemotherapeutic agents. 
EndoG-deficient PC3 cells, in contrast, were insensitive to these drugs in the range of 
concentrations used. 
Further study determined that cisplatin-induced death of prostate cancer cells can be 
prevented by EndoG silencing. Although EndoG is known to participate in cell death, it 
was necessary to determine whether the role of EndoG was the same in prostate cancer 
cells subjected to injury by cytotoxic agents as has been described in other cells. To test a 
causal relationship, EndoG was silenced in 22Rv1 cells by applying siRNA. To show that 
siRNA was delivered to the cells, fluorescent DY547-labeled siRNA was used. After 
DY547-siRNA transfection, 22Rv1 cells were exposed to 80 μM cisplatin, a concentration 
that had induced significant cell death in the above experiments. Next, TUNEL assay was 
conducted to measure DNA fragmentation. The assay showed the DNA fragmentation 
was decreased, indicating that silencing of EndoG leads to significant decrease of EndoG 
expression and protects cells from DNA fragmentation. As expected, EndoG silencing 
resulted in the increased viability of cisplatin-treated 22Rv1 cells as measured using 
clonogenic assay. The results suggest EndoG is responsible for cisplatin-induced death in 
prostate cancer cells. 
It is interesting that inhibition of DNA methylation induced EndoG and increased 
sensitivity of PC3 cells to cisplatin and etoposide. 5-aza-2’-deoxycytidine (decitabine), which 
is a DNA methylation inhibitor, caused hypomethylation of the EndoG promoter in PC3 
cells, induced EndoG mRNA and protein expression, and made the cells sensitive to the 
chemotherapy agents. Using McrBC-PCR method, we determined that the treatment of PC3 
cells with decitabine inhibited methylation of the CpG island in the EndoG gene. The same 
concentration of decitabine also increased EndoG expression as determined by real-time RT-
PCR and Western blotting. These data clearly suggested EndoG expression is regulated by 
DNA methylation. Importantly, the induction of EndoG by demethylation caused a 
significant increase in sensitivity to cisplatin and etoposide. 
Finally, the acetylation of histones by trichostatin A (TSA), a histone deacetylase inhibitor, 
induced EndoG expression in 22Rv1 cells, while it had no such effect in PC3 cells. These 
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data indicated EndoG may be regulated by methylation of its gene promoter, and partially 
by histone acetylation, and that EndoG is essential for prostate cancer cell death in the used 
models. Histone modification, in particular, histone acetylation, is another epigenetic 
mechanism that is important in regulation of genes in prostate cancer (Das et al., 2006; Egger 
et al., 2004; Wang et al., 2008; Yoo & Jones, 2006). To determine whether and how histone 
acetylation regulates EndoG expression, two prostate cancer cell lines were treated with 
TSA, and EndoG protein expression was studied using Western blotting. The exposure of 
the cells to TSA induced high levels of EndoG expression in EndoG-positive 22Rv1 cells, 
whereas in EndoG-deficient PC3 cells, EndoG was not induced. Again, EndoG induction 
by TSA caused increased sensitivity to cisplatin. These data demonstrated that chromatin 
acetylation is important for EndoG expression. Taken together with the above 
methylation experiments, these data indicate that DNA methylation plays a primary role 
in EndoG regulation as compared to histone acetylation. In other words, the CpG island 
of the EndoG gene has to be hypomethylated in order to allow regulation of EndoG 
expression by histone acetylation. 
4. Endonuclease delivery to prostate cancer cells and tumors 
Although these are attractive and potentially therapeutically useful approaches, 
modulations of endonuclease expression by DNA methylation or histone acetylation may 
not be a realistic approach because the specificity of epigenetic regulation is notoriously 
low. An alternative to these methods may be a gene delivery and overexpression in the 
target cancer cells. To determine whether overexpression of EndoG would make PC3 cells 
sensitive to the chemotherapy agents, the cells were transfected with human mature 
EndoG gene. To model chemotherapy in vitro, we used docetaxel, which is an FDA-
approved the first line chemotherapeutic agent in castration-refractory prostate cancer 
(Oudard et al., 2007; Ryan et al., 2001). Despite survival benefits with docetaxel based 
chemotherapy, prognosis for castration-refractory prostate cancer patients usually is poor 
and patients typically show rapid progression (Oudard et al., 2005; Wang et al., 2008). 
Progressive prostate cancer is associated with the development, and subsequent 
expansion of tumor cells that are resistant to apoptotic triggers and dysregulation of 
apoptosis is often characterized by insufficient apoptosis (Kruslin, 2009; Mori et al., 1996). 
Therefore a delivery of EndoG gene was expected to increase sensitivity of prostate cancer 
cells to docetaxel. 
As described below, this genetic manipulation resulted in significant increase of PC3 cells 
sensitivity to docetaxel and cisplatin in vitro. Similar results were obtained when PC3 cells 
were transfected with EndoG precursor gene suggesting that the drugs induce speedy 
processing of the protein to mature endonuclease. 
PC3 cells were chosen because they have very low expression of EndoG (Wang et al., 2008). 
Human EndoG gene (NM 004435.2) was cloned in the mammalian expression vector 
pECFP.N1 to result in an expression of EndoG protein fused with the enhanced cyan 
fluorescence protein (CFP). The expression of the chimeric protein was confirmed by 
fluorescent microscopy. Cells were then treated with docetaxel and cell death was measured 
using lactate dehydrogenase (LDH) release assay. This experiment showed the sensitivity of 
the PC3 cells expressing EndoG-CFP to docetaxel was much higher than the cells expressing 
CFP alone (Figure 1). The same result was also observed in cisplatin-induced cells death: 
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EndoG overexpression resulted in an over 4-folds elevation of cisplatin-induced cell death 
(data not shown). We also have compared mature EndoG gene and precursor EndoG gene 
overexpression cytotoxicity and their effects on cisplatin-induced cell death, and found that 
both types of EndoG had familiar effect (data not shown). 
 
 
 
Fig. 1. EndoG expression enhances prostate cancer cells’ sensitivity to docetaxel in vitro. Left 
panel: Cell death measured by LDH release assay in EndoG-expressing 22Rv1 and EndoG-
negative PC3 cells, which were exposed to varying concentrations of docetaxel for 24h (n=4, 
*p<0.05). Right panel: Cell death measured by LDH release assay in PC3 cells with or 
without EndoG precursor overexpression 24 hrs after exposure to varying concentrations of 
docetaxel (n=4, *p<0.05). 
Finally, parental PC3 cells and PC3 cells overexpressing human EndoG precursor were 
implanted in prostates of SCID mice to produce orthotopic tumors. The animals with 
xenografts were subjected to the docetaxel chemotherapy and the tumor size progression 
was monitored by high frequency ultrasound visualization. This experiment showed that 
EndoG-expressing tumors shrink in response to chemotherapy, while control tumors made 
of EndoG-negative parental PC3 cells were chemoresistant. To produce orthotopic 
xenografts, 8-weeks old male SCID mice were injected with human prostate cancer PC3 cells 
or EndoG gene-transfected PC3 cells by surgical orthotopic implantation. 2x105 cells were 
mixed with matrigel at 1:1 ratio (v/v) in a total volume of 20μl were injected in the left 
ventral prostate lobes after surgical opening of the lower abdomen skin and peritoneal 
membrane. Ultrasound image could identify prostate tumor as early for 6 days after 
implantation. Monitoring of the tumor growth showed that the prostate lobe eventually was 
occupied by the tumor and lost its original shape. At the 12th day, the mice received 
docetaxel (10mg/kg) via peritoneal cavity injection while the control mice received saline 
injection. Ultrasound images were taken at the 6, 12, and 18 days after orthotopic 
implantation. By day 18, PC3 xenograft tumors significantly grew up regardless of the 
docetaxel treatment; EndoG-PC3 xenografts without docetaxel treatment grew up less, 
while the docetaxel-treated EndoG-PC3 xenografts did not grow in size and instead shrunk 
(Figure 2). Histology analysis confirmed the EndoG overexpression in tumors, which 
coincided with positive TUNEL staining, thus confirming EndoG overexpression made 
xenografts sensitive to the docetaxel treatment. 
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Fig. 2. EndoG expression facilitates docetaxel sensitivity of orthotopic PC3 xenograft tumors. 
Human prostate cancer PC3 cells were transfected with EndoG precursor gene. Parental 
EndoG-deficient cells or EndoG-expressing PC3 cells were implanted in ventral prostate. 
Docetaxel (10 mg/kg) was administrated at the 12th day after implantation. Tumor sizes 
were monitored by intravital ultrasound sonography using VisualSonics Vevo 770 
instrument. Arrows indicate tumor edges.  
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5. Conclusive remarks 
Overall, our studies demonstrated that the expression and activity of the cytotoxic 
endonucleases are decreased in prostate cancer cells that are resistant to chemotherapy 
(Wang et al., 2008). This is consistent with previous studies of breast cancer, which also 
showed disappearance of DNase I in immortalized breast epithelial cells, and decrease of 
EndoG that coincided with dedifferentiation and invasiveness of breast cancer (Basnakian et 
al., 2006). EndoG is shown essential for prostate cancer cell death induced by chemotherapy. 
Expression of EndoG positively correlated with the sensitivity to chemotherapeutic agents 
cisplatin and etoposide, while the silencing of EndoG by siRNA in two cancer lines, 22Rv1 
and LNCaP, decreased the sensitivity of the cells to the chemotherapeutic agents. In PC3 cell 
line, which does not express EndoG, the chemotherapeutic agent 5-aza-2’-deoxycytidine 
caused hypomethylation of the EndoG promoter, induced EndoG expression, and made the 
cells sensitive to both cisplatin and etoposide. In our latest studies described above, the 
overexpression of EndoG in PC3 cells made them also sensitive to docetaxel in vitro and in 
vivo. Therefore these studies demonstrate the first application of endonucleases as a helper 
drug for the chemotherapy of prostate cancer. 
Because the mechanisms of chemo- and radiosensitivity of cells are very similar, these 
observations may be easily extrapolated to the radiotherapy of prostate cancer. Future 
studies may be necessary to determine the role of other epigenetic mechanisms in regulation 
of EndoG and their role in chemoresistance to prostate cancer and cancers of other organs. 
Chemotherapy is currently one of the frequently used therapeutic strategies for prostate 
cancer (Dyrstad et al., 2006; Kaku et al., 2006; Nakabayashi & Oh, 2006), and measurement 
of EndoG may be a potentially useful approach to evaluate chemosensitivity of cancer cells 
to determine optimal conditions for chemotherapy prior to the therapy. 
If further in vivo studies confirm our observation that EndoG is a potential key mediator of 
prostate cancer cell death regulated by the methylation of EndoG gene promoter, future 
epigenetic therapeutics will need to be targeted to EndoG. A development of this approach 
may lead to similar therapeutic strategies for cancer of other organs. 
Recent study determined that DNase I and EndoG, which represent most of DNase activity 
in prostate epithelial and many other cells and are linked in a single pathway, in which 
DNase I expression positively modulates EndoG expression (Yin et al., 2007). DNase I has 
the highest specific activity (per mg protein) among all known endonucleases, and it is the 
only endonuclease that can be directly incorporated into cells. The mechanisms of DNA 
destruction and the role in cell death are same between the two endonucleases. Therefore, it 
may not be necessary to deliver EndoG gene to prostate tumors and instead deliver DNase I 
protein packed in liposomes, which are attractive as vehicles because they have low toxicity. 
The only example of an endonuclease being applied for a therapy is human recombinant 
DNase I is used in complex therapy of cystic fibrosis. Future studies may lead to the first 
application of endonucleases as a helper drug for chemotherapy of prostate cancer. 
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